{"id":"NCT01865747","sponsor":"Exelixis","briefTitle":"A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma","officialTitle":"A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06","primaryCompletion":"2015-05-22","completion":"2021-01-15","firstPosted":"2013-05-31","resultsPosted":"2017-07-18","lastUpdate":"2021-04-27"},"enrollment":658,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Renal Cell Carcinoma"],"interventions":[{"type":"DRUG","name":"Cabozantinib tablets","otherNames":["XL184"]},{"type":"DRUG","name":"Everolimus (Afinitor) tablets","otherNames":[]}],"arms":[{"label":"Cabozantinib (XL184)","type":"EXPERIMENTAL"},{"label":"Everolimus (Afinitor)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with Everolimus (Afinitor) on progression-free survival (PFS) and overall survival (OS) in subjects with advanced renal cell cancer that has progressed after prior VEGFR tyrosine kinase inhibitor therapy.","primaryOutcome":{"measure":"Progression-free Survival (PFS)","timeFrame":"PFS is measured from the date of randomization until the date of first documented disease progression or date of death from any cause as determined by the Independent Radiology Committee (IRC) per RECIST 1.1, assessed for up to 17 months.","effectByArm":[{"arm":"Cabozantinib (XL184)","deltaMin":7.4,"sd":null},{"arm":"Everolimus (Afinitor)","deltaMin":3.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":205,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Chile","Czechia","Denmark","Finland","France","Germany","Hungary","Ireland","Italy","Netherlands","Poland","Portugal","Russia","Slovakia","South Korea","Spain","Sweden","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["37656041","34921022","34364385","31887537","31371341","29377755","29309249","27279544","26406150"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":131,"n":331},"commonTop":["Fatigue","Diarrhoea","Decreased Appetite","Nausea","Palmar-Plantar Erythrodysaesthesia Syndrome"]}}